Hamburg, Germany - 4 January 2011: Evotec AG (Frankfurt Stock Exchange, TecDAX: EVT; OTCBB: EVTCY) announced today that on 30 December 2010 it filed a Form 15F with the Securities and Exchange Commission (SEC) to deregister and terminate its reporting obligations under the U.S. Securities Exchange Act of 1934 (Exchange Act) for its American Depositary Shares (ADSs) and its ordinary shares underlying the ADSs. The deregistration and termination of reporting obligations is expected to take effect in March 2011.
This deregistration from the SEC is the final step following delisting from NASDAQ, which was initiated in November 2009. Evotec shares of course continue to be traded on Frankfurt Stock Exchange, Evotec's ADSs are traded on the over-the-counter (OTC) market in the U.S.
About Evotec AG
Evotec is a leader in the discovery and development of novel small molecule drugs with operational sites in Europe and Asia. The Company has built substantial drug discovery expertise and an industrialized platform that can drive new innovative small molecule compounds into the clinic. In addition, Evotec has built a deep internal knowledge base in the treatment of diseases related to neuroscience, pain, oncology, inflammation and metabolic diseases. Leveraging these skills and expertise the Company intends to develop best-in-class differentiated therapeutics and deliver superior science-driven discovery alliances with pharmaceutical and biotechnology companies. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Genentech, Novartis, Ono Pharmaceutical and Roche. Evotec has product candidates in clinical development and a series of preclinical compounds and development partnerships, including for example a strategic alliance with Roche for the EVT 100 compound family, subtype selective NMDA receptor antagonists for use in treatment-resistant depression and an alliance in the field of diabetes with Andromeda (Teva). For additional information please go to www.evotec.com.